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ABSTRACT 
Objective: To examine the effectiveness of a cognitive behavioural intervention delivered by mental 
health nurse practitioners (MHNPs) to patients with undifferentiated somatoform disorder (USD), 
compared to usual care. 
Methods: We conducted a cluster randomized trial among primary care patients with USD 
comparing the intervention to usual care. The intervention consisted of six sessions with the MHNP. 
Primary outcome was physical functioning (RAND-36 physical component summary score). 
Secondary outcomes were the RAND-36 mental component summary score and the eight subscales; 
anxiety and depression (Hospital Anxiety and Depression Scale) and somatic symptom severity 
(Patient Health Questionnaire-15). Outcomes were assessed at baseline, 2, 4 and 12 months. We 
analysed data using linear mixed models by intention-to-treat, and investigated effect modifiers. 
Results: Compared to usual care (n=87), the intervention group (n=111) showed an improvement in 
physical functioning (mean difference 2.24 [95% CI 0.51; 3.97]; p=.011), a decrease in limitations due 
to physical problems (mean difference 10.82 [95% CI 2.14; 19.49]; p.=0.015) and in pain (mean 
difference 5.08 [95% CI 0.58; 9.57]; p=.027), over 12 months. However effect sizes were small and 
less clinically relevant than expected. We found no differences for anxiety, depression and somatic 
symptom severity. Effects were larger and clinically relevant for patients with more recent symptoms 
and fewer physical diseases. 
Conclusion: The cognitive behavioural intervention was effective in improving pain and physical 
functioning components of patients' health. It was particularly suitable for patients with symptoms 
that had been present for a limited number of years and with few comorbid physical diseases. 
Trial registration: The trial is registered in the Dutch Trial Registry, www.trialregister.nl, under 
NTR4686.
INTRODUCTION 
Medically unexplained physical symptoms (MUPS) are a diverse mixture of symptoms for which 
(currently) a medical explanation is lacking and which are extremely common in primary care (1,2). In 
a small percentage of patients with MUPS a specific disorder may eventually prove to be the cause of 
the symptoms (3). Although most MUPS are self-limiting, symptoms may persist and cluster. In the 
latter case symptoms may fulfil the diagnostic criteria for the DSM-IV undifferentiated somatoform 
disorder (USD) (4). If physical symptoms are accompanied by disproportionate emotional, cognitive 
and behavioural reactions, they may fulfil DSM-5 diagnostic criteria for somatic symptom disorder 
(5). These psychiatric disorders are associated with a large burden of disease, poor quality of life, 
functional impairment, depression and anxiety (6,7). Additionally, general practitioners (GPs) may 
experience some MUPS patients as ‘difficult’ or even ‘heartsink’ (8–10). They face a dilemma 
between pursuing medical investigations which will probably yield nothing important and may cause 
harm on the one hand, and refraining from further investigations with a very small chance of 
overlooking a (treatable) disease on the other hand (11,12). Patients may feel uncertain, confused 
and distressed upon hearing that their symptoms do not currently fit with a diagnosable illness, and 
may regard that message as implying that their symptoms are feigned or “all in the mind” (13,14). 
This may negatively impact their attitude towards mental health interventions for their symptoms. 
Non-pharmacological interventions such as cognitive behavioural therapy (CBT) may improve 
functioning of patients with somatoform symptoms and reduce symptom severity (15). However, a 
German study found that only half of the patients with a somatoform disorder actually receive such 
mental health treatment (16), as CBT is commonly provided in secondary care or outside general 
practice. Patients and GPs may feel reluctant to turn to mental health services for physical 
symptoms. A CBT-based treatment provided in and suitable for primary care may therefore be a 
solution. 
In the Dutch healthcare system, all citizens are registered with a general practice. The GP serves as 
gatekeeper to other healthcare providers. A recent reform of the Dutch mental healthcare system 
aimed to reduce the gap between general practice and mental health treatment (17). In 2014, the 
mental health nurse practitioner (MHNP) was introduced within general practice and currently nearly 
all surgeries in the Netherlands (87% in 2016) employ one (18). Dutch MHNPs have received higher 
vocational training in nursing or psychology and work under the supervision of the GP (17). They 
deliver short-term interventions to patients with psychosocial problems, but their expertise in 
psychological techniques such as CBT can vary. 
The Dutch guideline on MUPS for GPs recommends that the MHNP offers treatment for MUPS when 
symptoms are mild to moderate (19). A standardized, evidence-based treatment could be helpful for 
patients and feasible for MHNPs to deliver. However, such an intervention has never been evaluated 
in this patient group. The main aim of this study was to examine the effectiveness of a new short-




We performed a multicentre, cluster randomized controlled trial with two parallel groups comparing 
a CBT-based intervention on top of usual care, to usual care alone. The study design is described in 
more detail elsewhere (20). 
We chose a cluster design in order to prevent contamination between patients in the same general 
practice and to prevent MHNPs from having to carry out the intervention with some of the patients 
and not carry it out with others, which might lead to contamination. 
Ethics 
The study was conducted according to the declaration of Helsinki (version 2013) and was approved 




Participants were recruited from general practices across the Netherlands, were aged 18 years and 
above and met the DSM-IV criteria for USD. Exclusion criteria were: having a medical or psychological 
disorder that explained the symptoms; having a severe psychiatric disorder (e.g. psychotic disorder); 
currently receiving psychological help for USD; having poor language skills or physical handicaps 
interfering with understanding the intervention or questionnaires. 
Inclusion procedure 
GPs selected patients aged 18 years and above from their electronic database, who had consulted 
the GP with one or more symptoms from “Robbins' list” (21) at least twice in the previous 3 months. 
Robbins' list consists of 23 physical symptoms that are associated with functional somatic syndromes 
and can be found in the trial protocol (20). GPs checked the list of selected patients for exclusion 
criteria. Patients identified as potentially eligible received concise information about the study and 
the Patient Health Questionnaire 15-item somatic symptom severity scale (PHQ-15) (22) by mail from 
their GP. Patients with a PHQ-15 score of at least 5 (low symptom severity) and who were interested 
in participation in the study received extensive information. Patients were then invited to participate 
in a clinical interview (Structure Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (23)) to assess 
DSM-IV criteria for USD. Trained members of the research team administered these interviews by 
telephone. Patients meeting the criteria for USD received an informed consent form. 
Intervention 
The intervention consisted of six individual sessions of 30 min each with a MHNP. The intervention 
comprised a combination of two CBT-based techniques: a modified version of the ‘consequences 
model’ for somatoform disorders and Problem-Solving Treatment (PST). The consequences model is 
frequently used in treatment of somatoform disorders in Dutch secondary care (24,25). It focusses 
on the consequences or problems that arise due to somatoform complaints rather than on their 
causes, which are by definition unknown. The model assumes that physical symptoms may lead to 
various consequences in the patient's daily life, which are in fact survival strategies in reaction to the 
physical symptoms. Although these survival strategies must have been beneficial initially (or they 
would not have been developed), they can aggravate symptoms and become harmful or devastating 
in the end. In the model, patients can improve their (physical) functioning and quality of life by 
strengthening the more beneficial, instead of the harmful, survival strategies in the end. Identified 
consequences or problems are then tackled using a CBT-based technique, which will be learned and 
applied by patients following the steps outlined in problem solving therapy (PST). PST is a practical 
treatment that is suitable for delivery by primary healthcare providers such as GPs and nurses 
(26,27). The goal was to support patients in developing survival strategies that are more helpful in 
the long run. 
Each session was described in detail in the intervention manual that all MHNPs received during their 
training. In session 1 the MHNP introduced and explained the treatment, the patient told the MHNP 
about their physical symptoms and consequences/problems in his/her life due to these symptoms. A 
consequence/problem was defined as something the patient would like to achieve but is unable to at 
the moment. In session 2 the MHNP explained the PST goals and steps. In each of the sessions 3 
through 6, the patient addressed a single consequence/problem, using the PST steps together with 
the MHNP. The goal was to stimulate people to practise improving their long-term problem solving 
skills, and to apply them to the consequences of their physical symptoms, but also to other problems 
in daily life. Patients applied the steps at home following written instructions. If not all the steps 
were covered during one session, they were addressed during the next session. 
MHNPs 
MHNPs followed two group training sessions lasting 3–3.5 h each. The training sessions were led by a 
clinical psychologist specialized in management of somatoform disorders. The training consisted of a 
theoretical part on USD, the consequences model and treatment rationale, and a practical part, in 
which MHNPs practiced PST. The clinical psychologist supervised the MHNPs during the study period. 
Usual care 
The usual care group did not receive any additional care, other than the usual care they received 
from their GP and any other healthcare providers they were referred to. 
Outcome measures 
Primary and secondary outcomes were assessed at baseline and 2, 4 and 12 months later. The 
measurements at 2 and 4 months corresponded to the intervention group being halfway through the 
intervention (3 sessions completed) and completing the intervention (6 sessions completed), 
respectively. Potential mediating variables were assessed at baseline and 2 and 4 months later. All 
outcome measures were assessed at the individual patient level. 
Primary outcome 
The primary outcome was the improvement in physical functioning during the total follow-up period, 
as measured by the physical component summary score (PCS) of the RAND-36 questionnaire. The 
PCS is one of the aggregated scores of the RAND-36, a validated questionnaire measuring health 
related quality of life. The raw scores were transformed into scores ranging from 0 to 100 with a 
higher score indicating better physical functioning (28). Item examples are “Does your health now 
limit you in lifting or carrying groceries? If so, how much?” and “How much bodily pain have you had 
during the past 4 weeks?” 
Secondary outcomes 
Secondary outcomes were the mental component summary score (MCS) and the eight subscales of 
the RAND-36 (physical functioning, role limitations due to physical health problems, role limitations 
due to emotional problems, social functioning, emotional well-being, energy/ fatigue, bodily pain and 
general health perceptions). The scores of each separate subscale range from 0 to 100, higher scores 
indicating better health. 
Depression and anxiety symptoms were measured by the Hospital Anxiety and Depression Scale 
(HADS) (29). This is an instrument with anxiety and depression subscales (HADS-A and HADS-D, 
respectively) with scores ranging from 0 to 21 for each scale. Higher scores indicate more severe 
symptoms. Somatization was measured with the PHQ-15 (22). This instrument has a score range of 
0–30, with higher scores indicating higher somatic symptom severity. 
Mediators  
We took the following potential mediators into account: problem-solving skills (Social Problem-
Solving Inventory) (30), health anxiety (Whitely Index) (31), cognitive and emotional representations 
of illness (brief version of the Illness Perception Questionnaire) (32), cognitive and behavioural 
responses to illness (Cognitive and Behavioural Responses Questionnaire) (33, 34), and level of 
perceived control (Pearlin Master Scale) (35). Data on these variables were collected at baseline, and 
at 2 and 4 months follow-up. 
In the intervention group, we assessed the strength of the therapeutic alliance with the revised 
short-form Working Alliance Inventory (WAI-SR)) (36), at 2 months and at 4 months. 
Process evaluation of the intervention 
In order to better interpret our quantitative findings, we conducted a process evaluation by 
interviewing MHNPs from the intervention group. When they had completed most sessions, all 15 
MHNPs were invited to participate in face-to-face interviews to evaluate their involvement in the 
trial; 13 accepted the invitation. The semi-structured interviews were based on a topic list with pre-
identified themes. 
At 4 months after baseline, patients in the intervention group were asked to answer 13 Likert items, 
evaluating their participation in the trial. The collected data were systematically analysed with both 
qualitative (interviews) and quantitative (questionnaire) methods. 
Sample size 
We aimed to detect a clinically relevant effect size of 0.4 sd on our primary outcome. We chose a 
two-sided significance level of 5% and a power of 80%. The allocation ratio was 1:1. We assumed a 
correlation coefficient of 0.5 for repeated measurements. Using linear mixed models with these 
values required a sample size of 74 patients per condition. We corrected for the cluster design with 
an expected average cluster size of 4 and assuming an ICC of 0.05 (37). Taking a potential dropout 
rate of 20% into account, we aimed to include 106 patients in each condition. 
Randomization and blinding 
At randomization, a cluster consisted of all participating general practices that employed one MHNP. 
An independent epidemiologist carried out concealed random allocation and assignment of clusters 
to the intervention group or control group by using a computer generated randomization list. She 
was not involved in the selection of general practices. In order to balance the size of the intervention 
and control groups, randomization was stratified according to cluster size (small: <5000 patients, and 
large: ≥5000 patients). Due to the nature of the intervention, it was not possible to blind researchers, 
GPs or patients to the allocation. MHNPs and GPs were informed about their allocation after signing 
a form that they agreed to participate. Patients were informed about their treatment allocation after 
they signed and returned the informed consent form. 
Statistical analyses 
We used descriptive statistics for baseline characteristics. The effect of the intervention on primary 
and secondary outcomes was analysed according to the intention-to-treat (ITT) principle (38). Linear 
mixed models analyses were used to take into account the dependence of repeated measurements 
in individual patients, without imputing missing data (39). Respondents were included if they had 
completed at least one follow-up measurement. For each outcome variable, we estimated the 
overall effect over time, and the effect per time point (2, 4 and 12 months after baseline). Time and 
the interaction between study group (intervention or control) and time were added to the models. 
For each outcome measure, we performed a crude and adjusted analysis over the total follow-up 
period of 12 months. The crude analysis was only adjusted for the baseline value of the particular 
outcome. In the adjusted analysis, we evaluated whether the following variables were actual 
confounders: gender, age, level of education, duration of symptoms, somatic symptom severity 
(PHQ-15), anxiety symptoms (HADS-A), depressive symptoms (HADS-D), number of comorbid 
diseases, time intervals between completing baseline questionnaire and 2-month follow-up, and 
between completing the 2-month and 4-month follow-up questionnaires. We adjusted for the latter 
two because these intervals were different between the intervention group and the usual care 
group, for logistic reasons. Variables found to be actual confounders were added to the adjusted 
model. 
For secondary outcomes, p-values should be interpreted cautiously due to multiple statistical 
comparisons, unless highly significant (e.g. p < .01). 
To evaluate whether we should adjust for clustering within general practice, this variable was added 
as an additional level to the linear mixed model analysis. As this did not improve the model 
(likelihood ratio test: p=-0.90; ICC<0.01), clusters were not included in the final analyses. 
All analyses were repeated applying the per protocol principle to the intervention group, as 
exploratory analyses. We defined three different per protocol populations: intervention patients who 
had 1) attended all 6 sessions with their MHNP (n=57); 2) attended all 6 sessions or less if their goals 
were achieved earlier (n=62); 3) attended at least 4 sessions (n=76). All control group patients were 
included in the per protocol analysis (n=87). 
We carried out additional analyses by adding interaction terms to evaluate whether any of the pre-
determined variables (age, gender, education level, symptom duration, somatic symptom severity 
(PHQ-15), physical comorbidity and anxiety and depressive symptoms (HADS)) were effect modifiers. 
These variables were chosen based on the Dutch multidisciplinary guideline for the management of 
MUPS and somatoform disorders, which identifies them as relevant factors in discerning patient 
profiles (40). Mediation analyses were carried out based on Krull & MacKinnon (41), using the Sobel-
Goodman test to determine significance. The relationship between primary outcome and working 
alliance was assessed using Pearson’s r. 
Cohen’s d for measuring effect size was calculated by dividing the regression coefficient of each 
outcome by its standard deviation. We used standard deviations for the total group at baseline. 
Data were analysed using IBM SPSS Statistics version 22 and Stata version 14. 
RESULTS 
Recruitment 
Recruitment of patients took place between August 2015 and March2017. Recruitment stopped 
when a total of 213 informed consent forms had been returned. Figure 1 provides an overview of the 
enrolment procedure. 
Baseline characteristics 
Socio-demographic and clinical baseline characteristics of the participants are provided in Table 1. 
The mean age of the total sample was 51.5 years (sd=16.3) and the majority of patients (74.5%) were 
female. There were more female patients (79.8%) in the control group than in the intervention group 
(70.3%) and the level of completed education was lower. The median duration of symptoms in the 
total sample was 5.7 years (IQR=2.7–15.7) and most commonly reported were musculoskeletal 
complaints (72.0%). Neurological symptoms were more common in the intervention group (35.1%) 
than in the control group (18.0%). 
Numbers analysed 
Data on the primary outcome on at least one follow-up assessment were available for 97/111 
(87.4%) patients in the intervention group and 75/87 (86.2%) patients in the control group. Figure 1 
provides more details on withdrawals. 
Primary outcome 
Fig. 2 visually represents the course of the RAND-36 PCS for both groups. The ITT analysis showed a 
significant intervention effect over the 12 month period on patients' physical functioning (PCS score 
difference 2.24 [95% CI 0.51; 3.97]; p=.011; Cohen's d=0.23) (Table 2). Results per time point are 
presented in Appendix A. There was a statistically significant difference at 4 months after baseline 
(PCS score difference 2.93 [95% CI 0.77; 5.09]; p=.008; Cohen's d=0.30). 
Secondary outcomes 
Significant intervention effects over 12 months were also found on patients' limitations in 
functioning due to physical health problems (RAND-36 role functioning/physical score difference 
10.82 [95% CI 2.14; 19.49]; p.=0.015; Cohen's d=0.33) and bodily pain (RAND-36 bodily pain score 
difference 5.08 [95% CI 0.58; 9.57]; p=.027; Cohen's d=0.23) (Table 2). 
When investigating the effects per time point (Appendix A), the largest and statistically significant 
differences were found at 4 months after baseline. Although there was no overall effect on the 
RAND-36 physical functioning subscale, there was a significant difference at 4 months (5.00 points 
[95% CI 0.28; 9.73]; p=.038; Cohen's d=0.20). 
No significant intervention effects were found for the remaining domains of health related quality of 
life, anxiety, depression and somatic symptom severity. 
Effect modification 
Reported duration of symptoms at baseline significantly modified the effect of our intervention on 
the RAND-36 PCS (p=0.011), bodily pain (p=0.048) and general health subscales (p=0.006). Physical 
comorbidity significantly modified the intervention effect on the RAND-36 PCS (p=0.026) and general 
health subscale (p=0.031). No other variable modified any of the effects. In order to report the 
results separately, we split each effect-modifying variable on its median. Table 3 summarizes the 
results per group and Appendix B provides results per time point. 
Generally, patients with a shorter duration of symptoms and fewer comorbid physical diseases 
showed improvement, as opposed to those with a longer duration of symptoms, who reported 
poorer general health after the intervention.  
Mediation 
None of the potential mediators actually mediated the effect on the primary outcome. With regard 
to the working alliance between patient and MHNP in the intervention group, a weak, but significant, 
positive correlation was found between the RAND-36 PCS change score between baseline and 4 
months and the WAI-SR bond scale (r=0.258, n=78, p=0.022) at 4 months after baseline. 
Exploratory analyses 
The results of the per protocol analyses are provided in Appendices C, D and E. For nearly all 
outcome variables the effect was similar to those in the ITT analyses. 
Evaluation by MHNPs and patients 
MHNPs were satisfied with the amount and content of training they received before delivering the 
intervention. Most found that 30 min was not enough for a single session. They reported that they 
generally adhered to the protocol but sometimes adjusted the length and pace of sessions by taking 
more time. MHNPs considered the CBT-based intervention to be a suitable technique for treating 
USD, that enhanced patients' problem-solving abilities and activated them in their daily life. MHNPs 
felt that most patients benefited from the intervention, as their functioning became less impaired, 
but thought that the intervention might not be effective for patients with comorbid physical and 
psychological disorders, psychosocial problems or a lower IQ. 
Most MHNPs would use (elements of) the protocol again in the future. Those who would use the 
protocol again said the treatment manual improved their proficiency in a CBT-based intervention, 
provided them with structure during sessions and a more problem-solving mindset. For future use, 
MHNPs recommended personalizing the number and pace of sessions to the patient, and offering 
other treatment methods alongside the CBT-based method, such as Acceptance and Commitment 
Therapy, psychoeducation, and physical activation. 
86 patients (77%) completed the patient evaluation questionnaire at 4 months after baseline. The 
(selected) results are provided in Table 4. The majority of patients (66%) rated the quality of the 
intervention as good, 11% as excellent, 14% as mediocre and 1 person (1%) as very poor. Half of the 
patients (51%) reported that the intervention helped them deal with their physical symptoms, 22% 
were neutral and 17% said it did not help. Most patients were fairly (42%), or extremely satisfied 
(25%) with the intervention and 20% were neutral. Only a few were (somewhat) unsatisfied (4%). 
More than half (54%) said they would certainly or probably recommend the intervention to a friend 
or family member with USD.1 
DISCUSSION 
Summary of findings 
Our intervention improved physical components of patients' health. Physical functioning improved, 
bodily pain and limitations due to physical problems and pain decreased. This effect was more 
pronounced for patients with physical symptoms that had been present for a limited number of years 
and with few comorbid physical diseases. These patients also experienced improved general health. 
Our study demonstrates that a relatively short and light intervention such as ours in primary care is 
suitable for patients with less persistent symptoms, but insufficient for those with more persistent 
symptoms. Our findings are supported by information from the interviews with the MHNPs, most of 
whom clearly distinguished between more severe an less severe patients, and reported that the 
latter benefited more from the intervention. Patients with symptoms that had lasted longer than the 
median duration deteriorated somewhat in their general health perceptions after our intervention. 
These patients assessed their health as poor and expected it to deteriorate further in the future. A 
possible explanation is that these patients, whose symptoms are already more difficult to treat due 
to their duration, became demoralized after receiving (possibly yet another) treatment that did not 
seem to help. In general, patients in the intervention group were satisfied with the intervention. 
Although most patients reported that they were satisfied with the intervention and would 
recommend it to a friend with MUPS, a smaller percentage was less positive. Presumably these were 
the intervention. 
Surprisingly, none of the variables that we hypothesized to be potential mediators actually mediated 
the effect on patients' well-being and symptoms. Thus, our study was unable to shed light on the 
mechanism of change. We did find a positive, though low, correlation with therapeutic alliance, 
which corresponds to previous findings of a positive therapeutic relationship being partly responsible 
for the effects of a psychological intervention and improving quality of life (42,43). 
Embedding in existing literature 
Overall we found statistically significant effects of our intervention, but effect sizes were small 
(d=0.22 for RAND-36 PCS, d=0.33 for role functioning/physical, and d=0.23 for bodily pain), and lower 
than we aimed for (0.4 sd for the RAND-36 PCS). Also, the effect on the primary outcome was not 
                                                          
1 Figures in this paragraph do not add to 100% due to missing values. 
clinically relevant (difference of 2.24 whereas a difference of 3–5 is considered clinically relevant 
(44)). However, effect sizes for the primary outcome were substantially higher in patients with a 
duration of symptoms shorter than the median (0.39) and with < 3 comorbid physical diseases (0.36). 
These are considered small, clinically relevant effect sizes. Our overall results are in line with previous 
findings from RCTs that investigated psychological interventions for patients with somatic complaints 
(15), where small to medium effect sizes are usually found on functional disability and quality of life. 
The effect sizes in our trial are also of similar magnitude to those demonstrated for interventions 
administered in primary care for other common mental disorders such as depression and anxiety 
(45,46). For patients who do not respond to brief primary care based interventions, more intense 
interventions could be offered (47,48). 
In previous research the effectiveness of psychological interventions for patients with multiple MUPS 
was investigated when provided by various healthcare providers, such as psychotherapists and GPs 
(49). We investigated the effectiveness of an intervention carried out by MHNPs, a new role in Dutch 
primary care. Interventions by nurse practitioners seem to have beneficial effects on patient 
satisfaction and quality of life in primary care patients with somatic problems (50). On the flip side, a 
recent study in Dutch general practices found that having a MHNP in the surgery resulted in MHNPs 
offering additional long consultations to patients with mental health problems, but did not reduce 
visits to the GP (17). Interventions delivered by MHNPs in general and for patients with somatoform 
complaints in particular must, therefore, be studied more extensively. Furthermore, incorporating 
other treatment methods such as physical exercise (49) or relaxation and mindfulness techniques 
(51) could be helpful for this patient group. 
Strengths and limitations 
This is the first study that examined the effects of an individual, CBT-based intervention by MHNPs 
for patients with USD versus usual care. We conducted the study in the actual setting of the general 
practice, making this treatment easier to implement. Another strength of this study is that we used 
qualitative data from process evaluation interviews with the MHNPs to deepen understanding of our 
results. 
Although the desired number of patients signed an informed consent form (n=213), not all of them 
completed all of the measurements. The dropout rate also turned out higher than expected (27% 
rather than 20%). This might be attributed to our case-finding (persons might be less motivated to 
change), a relatively long follow-up period (12 months) and the length of the questionnaires. 
Furthermore, we used the diagnosis of USD according to the, now outdated, DSM-IV, as our trial was 
initiated in the transition period from DSM-IV to DSM-5, and a diagnostic interview for the DSM-5 
was not available yet. The entire DSM-IV category ‘somatoform disorders’, to which USD belonged 
(4), has been replaced by ‘somatic symptom disorder’ (SSD) in the DSM-5 (5). A study comparing 
these diagnostic criteria found that patients with SSD always fulfil the criteria for USD, and have 
more severe symptoms and a lower quality of life (52). Therefore, as all SSD patients fulfil the criteria 
for USD, our findings could be generalizable to patients with SSD. However, considering that the 
latter are a more severe group and as our findings show that patients with a longer duration of 
symptoms do not benefit from our intervention, this needs to be verified in future studies. 
We opted for cluster randomization, in order to keep the effect of the intervention as pure as 
possible, so that trained MHNPs would not have to switch between providing and not providing the 
intervention to similar patients. However, the choice to use cluster randomization also implied using 
larger clusters and a more complex definition of cluster because individual various MHNPs working in 
the same surgery also worked part-time in separate other surgeries. 
A final point of consideration is that our trial was conducted in the Dutch healthcare setting, in which 
every citizen has access to general practice and virtually every general practice has an employed 
MHNP. Our results may be less generalizable to countries with different healthcare systems. 
CONCLUSION 
Our study demonstrated promising results for a nurse-led CBT-based intervention for patients with 
USD over usual primary care. The short-term and relatively light intervention appears effective for 
patients with a shorter symptom duration and with few other somatic diseases. 
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Intention to treat analysis: n=75Intention to treat analysis: n=97
Figure 1. Flow of study participants  
* For the intervention group, a cluster was composed by matching MHNPs to all participating general practices where the 
MHNP works and to all other MHNPs who also worked in these general practices.  
GP General practitioner; MHNP mental health nurse practitioner; PHQ-15 Patient Health Questionnaire 15-item somatic 
symptom severity scale; SCID-I Structured Clinical Interview for DSM-IV Axis I Disorders  
  
 
Figure 2. 12-month course of physical functioning as measured with the RAND-36 Physical Component Summary score (PCS) 
 
Table 1. Patients’ baseline characteristics 
Characteristics Intervention group 
(n=111) 
Control group (n=89) a Total sample (n=200) b 
Age, mean (sd) 53.00 (15.47) 49.69 (17.13) 51.53 (16.3) 
Female 78 (70.3%) 71 (79.8%) 149 (74.5%) 
Both parents born in the 
Netherlands 
90 (81.1%) 72 (80.9%) 162 (81.0%) 
Educational level   
 Low 8 (7.3%) 7 (8.0%) 15 (7.6%) 
 Medium 58 (52.3%) 54 (62.1%) 112 (56.9%) 
 High education 44 (40.0%) 26 (29.8%) 70 (35.5%) 
Work status c  
 Employed 43 (38.7%) 36 (40.4.%) 79 (39.5%) 
 Unemployed 68 (61.3%) 53 (59.6%) 121 (60.5%) 
Living situation  
 Alone 28 (25.2%) 23 (25.8%) 51 (25.5%) 
 Not alone 83 (74.8%) 66 (74.2%) 149 (74.5%) 
Symptom duration in 
years (self-report), 
median (IQR) 




 Musculoskeletal 78 (70.3%) 66 (74.2%) 144 (72.0%) 
 General and 
 unspecified 
41 (36.9%) 36 (40.4%) 77 (38.5%) 
 Neurological 39 (35.1%) 16 (18.0%) 55 (27.5%) 
 Psychological 19 (17.1%) 18 (20.2%) 37 (18.5%) 
 Digestive 11 (9.9%) 7 (7.9%) 18 (9.0%) 
Number of comorbid 
physical diseases, mean 
(sd) 
3.16 (2.50) 3.34 (2.41) 3.24 (2.46) 
Most reported comorbid 
physical diseases c 
 
 Back problems 79 (71.2%) 63 (70.8%) 142 (71.0%) 
 Pulmonary 40 (36.0%) 28 (31.5%) 68 (34.0%) 
 Neurological 35 (31.5%) 31 (34.8%) 66 (33.0%) 
Number of self-report 
comorbid psychiatric 
disorders, mean (sd) 
0.69 (0.91) 0.71 (1.19) 0.70 (1.04) 
Most reported comorbid 
psychiatric disorders c 
 
 Distress/burn-out 27 (24.5%) 18 (20.9%) 45 (23.0%) 
 Depression 26 (23.4%) 17 (19.5%) 43 (21.7%) 
 Anxiety 19 (17.1%) 16 (17.4%) 34 (17.3%) 
RAND-36  
 PCS (primary outcome) 50.22 (9.89) 49.64 (9.81) 49.97 (9.83) 
 MCS 49.80 (9.97) 50.22 (10.93) 49.99 (10.38) 
 Physical functioning  62.78 (25.08) 59.25 (26.12) 61.23 (25.54) 
 Role 
 functioning/physical 
21.62 (32.59) 25.29 (32.84) 23.21 (32.67) 
 Role 
 functioning/emotional 
56.52 (44.13) 52.61 (46.01) 54.84 (44.87) 
 Social functioning 55.63 (27.73) 57.76 (27.84) 56.57 (27.73) 
 Bodily pain 46.24 (21.31) 45.79 (22.19) 46.04 (21.64) 
 Emotional well-being  59.72 (17.04) 60.43 (20.23) 60.03 (18.43) 
 Energy/fatigue 36.89 (16.90) 38.65 (15.95) 37.65 (16.48) 
 General health 43.81 (17.64) 41.43 (16.25) 42.78 (17.05) 
Anxiety (HADS-A) 7.89 (3.80) 7.69 (4.52) 7.80 (4.11) 
Depression (HADS-D) 7.00 (3.86) 7.52 (4.23) 7.22 (4.02) 
Somatic symptom 
severity (PHQ-15) 
13.63 (4.89) 13.47 (4.43) 13.56 (4.69) 
Results are expressed as n (%) unless stated otherwise, and in mean (sd) for the RAND-36, HADS and PHQ-15. 
Abbreviations: HADS: Hospital Anxiety and Depression Scale; MCS: Mental Component Summary Score; MUS: medically 
unexplained symptoms; PCS: Physical Component Summary Score; PHQ-15: Patient Health Questionnaire 15-item somatic 
symptom severity scale; sd: standard deviation 
a 89 patients completed items on demographic characteristics, but 87 patients completed the primary outcome. Therefore, 
due to missing values, the available n ranged from 87-89. 
b Due to missing values the available n ranged from 188-200. 
c More than one answer option was permitted, so numbers do not necessarily add up to 100% 
  
Abbreviations: 95%CI: 95% Confidence Interval; HADS-A: Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D: 
Hospital Anxiety and Depression Scale-Depression subscale; MCS: Mental Component Summary Score; PCS: Physical 
Component Summary Score; PHQ-15: Patient Health Questionnaire 15-item somatic symptom severity scale  
a: adjusted for (if necessary): gender, age, level of education, duration of symptoms, somatic symptom severity (PHQ-15), 
anxiety symptoms (HADS-A), depressive symptoms (HADS-D), number of comorbid physical diseases, time interval baseline 
– 2-months follow-up, time interval baseline – 4-months follow-up 
* p<0.05 
  




RAND-36 Physical component 
summary score (PCS) 
Crude analyses Adjusted analyses a 
B (95% CI) p-value B (95% CI) p-value 
 










 Mental component 
 summary score (MCS) 
-0.55 (-2.47 to 1.37) 0.57 -0.35 (-2.22 to 1.52) 0.71 
 Physical functioning 1.47 (-2.08 to 5.02) 0.42 2.33 (-1.40 to 6.06) 0.21 
 Role 
 functioning/physical 
7.17 (-1.16 to 15.50) 0.091 10.82 (2.14 to 19.49) 0.015* 
 Role 
 functioning/emotional 
-2.14 (-11.63 to 
7.36) 
0.66 1.41 (-8.29 to 11.10) 0.78 
 Social functioning 2.65 (-2.85 to 8.14) 0.35 2.66 (-3.09 to 8.41) 0.37 
 Bodily pain 3.98 (-0.31 to 8.27) 0.069 5.08 (0.58 to 9.57) 0.027* 
 Emotional well-being -0.77 (-3.88 to 2.35) 0.63 -0.13 (-3.28 to 3.02) 0.93 
 Energy/fatigue 2.56 (-0.64 to 5.75) 0.12 1.98 (-1.24 to 5.20) 0.23 
 General health -0.28 (-3.90 to 3.34) 0.88 0.05 (-3.91 to 4.02) 0.98 
Anxiety symptoms (HADS-A) 0.30 (-0.33 to 0.94) 0.35 0.33 (-0.29 to 0.94) 0.30 
Depressive symptoms (HADS-
D) 
-0.06 (-0.66 to 0.55) 0.86 -0.23 (-0.89 to 0.43) 0.49 
Somatic symptom severity 
(PHQ-15) 
-0.51 (-1.43 to 0.40) 0.27 -0.69 (-1.64 to 0.24) 0.15 




Table 3. Results of crude mixed models analyses per group for symptom duration and physical comorbidity 
 Symptom duration below median 
(n=70-98) 
Symptom duration above median 
(n=72-98) 
Overall difference 
B (95% CI) 
p-value Overall difference 














 Bodily pain 
 
 










 General health 5.74 (0.96 to 10.52) 0.019* -5.98 (-11.09 to -0.86) 0.022* 
 
 0-2 comorbid physical diseases 
(n=69-91) 
3 or more comorbid physical diseases (n=75-
106) 
Overall difference 
B (95% CI) 
p-value Overall difference 




















-3.09 (-8.16 to 1.98) 
 
0.23 
Table 4. (Selected) results from the patient evaluation questionnaire* 
 
1. Did the individual training 
help you deal better with your 
physical complaints? 
Yes, it helped me a lot Yes, it helped me 
somewhat 
Neutral No, it did not help me No, it aggravated my 
complaints 
 4.6% 46.0% 21.8% 17.2% 0% 
2. What did you think of the 
quality of the individual training 
that you followed? 
Excellent Good Medium Bad Very bad 
 10.3% 65.5% 13.8% 0% 1.1% 
 
3. Did the intervention meet 
your expectations? 
All my expectations 
were met 
Most of my 
expectations were met 
Some of my 
expectations were met 
Only a few of my 
expectations were met 
None of my 
expectations were met 
 8.0% 35.6% 21.8% 18.4% 5.7% 
 
4. How satisfied are you in 
general with the intervention 
you received? 
Very satisfied Somewhat satisfied Neutral Somewhat unsatisfied Very unsatisfied 
 25.3% 41.4% 19.5% 3.4% 1.1% 
 
5. Imagine that someone you 
know happens to have 
unexplained physical 
complaints, would you 
recommend this intervention? 
 
Yes, definitely Yes, I think so Maybe No, I don’t think so No, definitely not 
 23.0% 31.0% 26.4% 11.5% 0% 
 
6. Imagine that you encounter 
unexplained physical symptoms 
again in the future, would you 
follow this intervention again 
with your MHNP? 
 
Yes, definitely Yes, I think so Maybe No, I don’t think so No, definitely not 
 17.2% 14.9% 28.7% 26.4% 3.4% 
 
* Numbers do not add up to 100% due to missing values 
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Adjusted analyses a 
 Baseline 50.22 (9.89) 49.64 (9.81) B (95% CI) p-value B (95% CI) p-value 
 2 months 50.45 (9.67) 49.18 (9.01) 1.25 (-0.81 to 3.30) 0.24 1.66 (-0.52 to 3.84) 0.14 
 4 months 51.28 (10.57) 48.23 (8.77) 2.08 (0.05 to 4.12) 0.045* 2.93 (0.77 to 5.09) 0.008* 
 12 months 51.21 (9.93) 48.09 (10.53) 2.10 (-0.02 to 4.23) 0.053 2.09 (-0.14 to 4.33) 0.066 













Adjusted analyses a 
 Baseline 49.80 (9.97) 50.22 (10.93) B (95% CI) p-value B (95% CI) p-value 
 2 months 50.05 (10.13) 50.12 (10.28) -0.02 (-2.46 to 2.43) 0.99 0.02 (-2.37 to 2.42) 0.99 
 4 months 49.67 (10.09) 50.25 (10.26) -0.69 (-3.10 to 1.73) 0.58 -0.67 (-3.10 to 1.76) 0.59 
 12 months 49.68 (9.22) 50.44 (10.51) -1.02 (-3.54 to 1.51) 0.43 -0.44 (-2.97 to 2.08) 0.73 







Crude analyses Adjusted analyses a 
 Baseline 62.78 (25.08) 59.25 (26.12) B (95% CI) p-value B (95% CI) p-value 
 2 months 61.68 (25.81) 57.79 (25.44) 0.04 (-4.48 to 4.57) 0.99 0.56 (-4.16 to 5.28) 0.82 
 4 months 66.42 (25.36) 58.71 (26.70) 3.66 (-0.84 to 8.16) 0.11 5.00 (0.28 to 9.73) 0.038* 
 12 months 67.77 (23.61) 60.63 (28.98) 0.65 (-4.05 to 5.35) 0.79 1.35 (-3.63 to 6.13) 0.62 







Crude analyses Adjusted analyses a 
 Baseline 21.62 (32.59) 25.29 (32.84) B (95% CI) p-value B (95% CI) p-value 
 2 months 28.45 (36.00) 29.96 (35.71) 3.56 (-7.43 to 14.56) 0.53 7.18 (-4.33 to 18.69) 0.22 
 4 months 35.51 (41.47) 27.38 (34.20) 9.33 (-1.54 to 20.20) 0.093 13.57 (2.21 to 24.92) 0.019* 
 12 months 38.75 (41.13) 30.24 (38.18) 8.77 (-2.65 to 20.20) 0.13 11.51 (-0.35 to 
23.37) 
0.057 







Crude analyses Adjusted analyses a 
 Baseline 56.52 (44.13) 52.61 (46.01) B (95% CI) p-value B (95% CI) p-value 
 2 months 58.24 (44.96) 57.21 (44.12) -3.21 (16.19 to 9.77) 0.63 0.03 (-13.26 to 
13.31) 
1.00 
 4 months 58.62 (43.42) 58.10 (45.64) -2.45 (-15.26 to 
10.36) 
0.71 0.66 (-12.47 to 
13.78) 
0.92 
 12 months 62.71 (43.76) 60.22 (45.10) -0.62 (-14.10 to 
12.86) 
0.93 3.55 (-10.21-17.31) 0.61 







Crude analyses Adjusted analyses a 
 Baseline 55.63 (27.73) 57.76 (27.84) B (95% CI) p-value B (95% CI) p-value 
 2 months 64.49 (25.91) 62.87 (24.24) 2.44 (-4.54 to 9.41) 0.45 2.04 (-5.31 to 9.40) 0.59 
 4 months 64.77 (24.75) 63.19 (26.533) 1.85 (-5.05 to 8.75) 0.60 2.22 (-5.05 to 9.50) 0.55 
 12 months 67.59 (24.83) 63.10 (27.63) 3.78 (-3.42 to 10.98) 0.30 3.74 (-3.80 to 11.28) 0.33 
 Overall effect n/a n/a 2.65 (-2.85 to 8.14) 0.35 2.66 (-3.09 to 8.41) 0.37 




Crude analyses Adjusted analyses a 
 Baseline 46.24 (21.31) 45.79 (22.19) B (95% CI) p-value B (95% CI) p-value 
 2 months 52.85 (21.71) 49.55 (24.01) 3.26 (-2.22 to 8.74) 0.24 4.45 (-1.24 to 10.14) 0.13 
 4 months 56.77 (21.42) 50.17 (21.77) 4.98 (-0.44 to 10.40) 0.072 6.45 (0.83 to 12.08) 0.025* 
 12 months 57.19 (20.20) 51.21 (25.89) 3.69 (-1.97 to 9.34) 0.20 4.08 (-1.75 to 9.91) 0.17 







Crude analyses Adjusted analyses a 
 Baseline 59.72 (17.04) 60.43 (20.23) B (95% CI) p-value B (95% CI) p-value 
 2 months 60.18 (17.43) 60.50 (20.29) 0.04 (-3.91 to 4.00) 0.98 0.22 (-3.80 to 4.23) 0.92 
 4 months 63.91 (18.61) 63.77 (19.30) -0.12 (-4.04 to 3.80) 0.95 0.85 (-3.14 to 4.85) 0.68 
 12 months 62.76 (16.84) 64.51 (19.81) -2.36 (-6.43 to 1.71) 0.23 -1.68 (-5.79 to 2.44) 0.43 







Crude analyses Adjusted analyses a 
 Baseline 36.89 (16.90) 38.65 (15.95) B (95% CI) p-value B (95% CI) p-value 
 2 months 40.19 (17.18) 38.80 (15.81) 3.31 (-0.87 to 7.49) 0.12 2.08 (-2.15 to 6.31) 0.34 
 4 months 42.82 (18.12) 41.36 (14.32) 2.22 (-1.91 to 6.36) 0.29 1.76 (-2.44 to 5.96) 0.41 
 12 months 46.71 (18.70) 46.06 (17.81) 2.05 (-2.25 to 6.36) 0.35 1.90 (-2.43 to 6.24) 0.39 







Crude analyses Adjusted analyses a 
 Baseline 43.81 (17.64) 41.43 (16.25) B (95% CI) p-value B (95% CI) p-value 
 2 months 44.51 (17.86) 43.50 (16.67) -0.60 (-3.82 to 5.02) 0.79 0.64 (-4.11 to 5.38) 0.79 
 4 months 47.14 (20.38) 47.54 (18.06) -1.53 (-5.91 to 2.84) 0.49 -1.21 (-5.92 to 3.50) 0.62 
 12 months 49.09 (19.37) 47.06 (17.47) 0.28 (-4.23 to 4.79) 0.91 0.63 (-4.21 to 5.46) 0.80 







Crude analyses Adjusted analyses a 
 Baseline 7.89 (3.80) 7.69 (4.52) B (95% CI) p-value B (95% CI) p-value 
 2 months 8.47 (4.22) 7.32 (4.28) 0.48 (-0.34 to 1.29) 0.25 0.51 (-0.29 to 1.31) 0.21 
 4 months 7.46 (4.07) 6.72 (4.43) 0.19 (-0.62 to 1.00) 0.65 0.17 (-0.63 to 0.98) 0.67 
 12 months 6.89 (4.09) 6.26 (4.41) 0.24 (-0.60 to 1.08) 0.58 0.32 (-0.50 to 1.15) 0.44 







Crude analyses Adjusted analyses a 
 Baseline 7.00 (3.86) 7.52 (4.23) B (95% CI) p-value B (95% CI) p-value 
 2 months 6.93 (3.91) 7.26 (4.29) -0.05 (-0.83 to 0.72) 0.89 -0.12 (-0.93 to 0.68) 0.77 
 4 months 6.29 (4.04) 6.62 (4.31) -0.06 (-0.84 to 0.71) 0.87 -0.21 (-1.02 to 0.60) 0.61 
 12 months 5.83 (4.15) 6.29 (4.54) -0.05 (-0.85 to 0.75) 0.90 -0.34 (-1.17 to 0.48) 0.42 







Crude analyses Adjusted analyses a 
 Baseline 13.63 (4.89) 13.47 (4.43) B (95% CI) p-value B (95% CI) p-value 
 2 months 13.13 (5.36) 13.74 (5.23) -1.06 (-2.25 to 0.14) 0.083 -1.19 (-2.42 to 0.04) 0.057 
 4 months 12.83 (5.20) 12.74 (4.95 -0.05 (-1.25 to 1.14) 0.93 -0.33 (-1.56 to 0.91) 0.60 
 12 months 11.86 (5.27) 12.03 (5.78) -0.04 (-1.62 to 0.89) 0.56 -0.47 (-1.75 to 0.80) 0.47 
 Overall effect n/a n/a -0.51 (-1.43 to 0.40) 0.27 -0.69 (-1.64 to 0.24) 0.15 
Abbreviations: 95%CI: 95% Confidence Interval; HADS-A, Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D, Hospital Anxiety and Depression Scale-Depression subscale; n/a: not 
applicable; ITT: Intention to Treat; MCS: Mental Component Summary Score; PCS: Physical Component Summary Score; PHQ-15: Patient Health Questionnaire 15-item somatic symptom 
severity scale; sd: standard deviation 
a adjusted for (if necessary): gender, age, level of education, duration of symptoms, somatic symptom severity (PHQ-15), anxiety symptoms (HADS-A), depressive symptoms (HADS-D), number 









Symptom duration below median 
(n=70-98) 













Symptom duration below 
median 
Symptom duration above 
median 
 
 Baseline 51.52 (9.80) 51.20 (10.05) 48.78 (9.97) 48.20 (9.57) B (95% CI) p-value B (95% CI) p-value 
 2 months 52.08 (9.94) 49.95 (9.69) 48.88 (9.25) 48.52 (8.65) n/a n/a n/a n/a 
 4 months 54.90 (9.87) 50.74 (8.97) 47.41 (10.15) 46.00 (8.21) n/a n/a n/a n/a 
 12 months 54.13 (9.02) 48.63 (12.00) 48.01 (10.13) 47.42 (9.38) n/a n/a n/a n/a 
 Overall 
 effect 
n/a n/a n/a n/a 3.83 (1.57 to 
6.09) 






Symptom duration below median 
(n=70-98) 











Symptom duration below 
median 




(mean, sd) (mean, sd)  
 
 Baseline 48.35 (22.74) 45.51 (22.36) 43.92 (19.76) 45.56 (22.30) B (95% CI) p-value B (95% CI) p-value 
 2 months 57.05 (23.05) 50.95 (26.21) 48.68 (19.58) 48.34 (22.81) n/a n/a n/a n/a 
 4 months 62.59 (19.86) 52.68 (22.67) 50.58 (21.77) 46.94 (21.03) n/a n/a n/a n/a 
 12 months 62.34 (18.00) 50.80 (27.53) 51.83 (21.44) 50.78 (24.86) n/a n/a n/a n/a 
 Overall 
 effect 
n/a n/a n/a n/a 6.94 (1.05 to 
12.84) 






Symptom duration below median 
(n=70-98) 













Symptom duration below 
median 
Symptom duration above 
median 
 
 Baseline 44.53 (17.67) 43.33 (18.00) 43.17 (17.88) 39.77 (14.74) B (95% CI) p-value B (95% CI) p-value 
 2 months 46.36 (16.51) 40.69 (18.50) 42.68 (19.38) 45.45 (15.10) n/a n/a n/a n/a 
 4 months 49.64 (19.41) 47.90 (20.77) 43.69 (20.78) 47.04 (16.02) n/a n/a n/a n/a 
 12 months 53.10 (18.21) 45.00 (19.53) 22.87 (20.15) 48.09 (15.52 n/a n/a n/a n/a 
 Overall 
 effect 
n/a n/a n/a n/a 5.74 (0.96 to 
10.52) 







0-2 comorbid physical diseases 
(n=69-91) 













0-2 comorbid physical diseases 3 or more comorbid physical 
diseases 
 Baseline 53.64 (9.38) 55.07 (8.78) 53.64 (9.38) 55.07 (8.78) B (95% CI) p-value B (95% CI) p-value 
 2 months 53.65 (8.48) 52.85 (8.20) 53.65 (8.48) 52.85 (8.20) n/a n/a n/a n/a 
 4 months 55.24 (9.63) 51.47 (8.51) 55.24 (9.63) 51.47 (8.51) n/a n/a n/a n/a 
 12 months 55.38 (8.20) 50.85 (10.21) 55.38 (8.20) 50.85 (10.21) n/a n/a n/a n/a 
 Overall 
 effect 
n/a n/a n/a n/a 3.55 (1.13 to 
5.97) 








0-2 comorbid physical diseases 
(n=69-91) 













0-2 comorbid physical diseases 3 or more comorbid physical 
diseases 
 Baseline 49.01 (16.64) 46.41 (14.49) 49.01 (16.64) 46.41 (14.49) B (95% CI) p-value B (95% CI) p-value 
 2 months 49.39 (17.25) 46.21 (16.18) 49.39 (17.25) 46.21 (16.18) n/a n/a n/a n/a 
 4 months 54.97 (19.96) 53.50 (16.20) 54.97 (19.96) 53.50 (16.20) n/a n/a n/a n/a 
 12 months 55.49 (18.57) 49.31 (15.91) 55.49 (18.57) 49.31 (15.91) n/a n/a n/a n/a 
 Overall 
 effect 
n/a n/a n/a n/a 2.38 (-2.60 to 
7.36) 
0.35 -3.09 (-8.16 to 
1.98) 
0.23 




Appendix C. Results of the mixed models per protocol analyses with the group of intervention patients who 





Crude analyses Adjusted analyses a 
B (95% CI) p-value B (95% CI) p-value 
 
























 Physical functioning 2.21 (-2.01 to 6.43) 0.30 2.54 (-1.68 to 6.76) 0.24 
 Role 
functioning/physical 
7.87 (-1.72 to 
17.47) 





-0.03 (-10.95 to 
10.90) 
1.00 0.29 (-10.62 to 
11.20) 
0.96 
 Social functioning 3.10 (-3.04 to 9.24) 0.32 1.88 (-4.27 to 8.04) 0.55 
 Bodily pain 4.29 (-0.53 to 9.11) 0.081 4.29 (-0.53 to 9.11) 0.081 
 Emotional well-being -1.09 (-4.79 to 
2.61) 
0.56 -0.80 (4.44 to 2.85) 0.67 
 Energy/fatigue 3.03 (-0.60 to 6.65) 0.10 2.00 (-1.52 to 5.51) 0.27 
 General health 1.15 (-3.13 to 5.42) 0.60 0.15 (-4.46 to 4.75) 0.95 
Anxiety symptoms 
(HADS-A) 
0.19 (-0.53 to 0.91) 0.60 0.36 (-0.32 to 1.04) 0.30 
Depressive symptoms 
(HADS-D) 
-0.23 (-0.95 to 
0.49) 
0.53 -0.21 (-0.96 to 
0.53) 
0.58 
Abbreviations: 95%CI: 95% Confidence Interval; HADS-A: Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D: 
Hospital Anxiety and Depression Scale-Depression subscale; MCS: Mental Component Summary Score; MHNP: mental 
health nurse practitioner; PCS: Physical Component Summary Score; PHQ-15: Patient Health Questionnaire 15-item 
somatic symptom severity scale  
a adjusted for (if necessary): gender, age, level of education, duration of symptoms, somatic symptom severity (PHQ-15), 
anxiety symptoms (HADS-A), depressive symptoms (HADS-D), number of comorbid physical diseases, time interval baseline 
– 2-months follow-up, time interval baseline – 4-months follow-up 
* p <0.05  
Somatic symptom 
severity (PHQ-15) 
-0.92 (-1.95 to 
0.11) 
0.080 -0.54 (-1.51 to 
0.43) 
0.28 
Appendix D. Results of the mixed models per protocol analyses with the group of intervention patients who 





Crude analyses Adjusted analyses a 
B (95% CI) p-value B (95% CI) p-value 
 























 Physical functioning 1.98 (-2.13 to 6.09) 0.35 1.71 (-2.38 to 5.80) 0.41 
 Role 
functioning/physical 
8.70 (-0.62 to 
18.03) 
0.067 9.99 (0.30-19.68) 0.043* 
 Role 
functioning/emotional 
1.22 (-9.35 to 
11.79) 
0.82 1.19 (-9.18 to 
11.55) 
0.82 
 Social functioning 4.14 (-1.85 to 
10.12) 
0.18 2.55 (-3.46 to 8.56) 0.41 
 Bodily pain 4.37 (-0.27 to 9.02) 0.065 3.85 (-0.65 to 8.36) 0.093 
 Emotional well-being -0.45 (-4.07 to 
3.17) 
0.81 -0.57 (-4.16 to 
3.01) 
0.76 
 Energy/fatigue 3.97 (0.39 to 7.54) 0.030* 2.66 (-0.84 to 6.15 0.14 
 General health 1.15 (-2.99 to 5.29) 0.59 0.08 (-4.41 to 4.56) 0.97 
Anxiety symptoms 
(HADS-A) 
0.10 (-0.59 to 0.80) 0.77 0.38 (-0.30 to 1.05) 0.27 
Abbreviations: 95%CI: 95% Confidence Interval; HADS-A: Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D: 
Hospital Anxiety and Depression Scale-Depression subscale; MCS: Mental Component Summary Score; MHNP: mental 
health nurse practitioner; PCS: Physical Component Summary Score; PHQ-15: Patient Health Questionnaire 15-item 
somatic symptom severity scale  
a adjusted for (if necessary): gender, age, level of education, duration of symptoms, somatic symptom severity (PHQ-15), 
anxiety symptoms (HADS-A), depressive symptoms (HADS-D), number of comorbid physical diseases, time interval baseline 
– 2-months follow-up, time interval baseline – 4-months follow-up 
* p <0.05  
Depressive symptoms 
(HADS-D) 
-0.31 (-1.00 to 
0.39) 





-1.04 (-2.03 to -
0.04) 
0.041* -0.58 (-1.52 to 
0.36) 
0.23 
Appendix E. Results of the mixed models per protocol analyses with the group of intervention patients who 





Crude analyses Adjusted analyses a 
B (95% CI) p-value B (95% CI) p-value 
 
























 Physical functioning 2.04 (-1.78 to 5.86) 0.30 2.10 (-1.82 to 6.01) 0.29 
 Role 
functioning/physical 
8.57 (-0.32 to 
17.47) 





0.55 (-9.61 to 
10.71) 
0.92 -0.23 (-10.65 to 
10.18) 
0.97 
 Social functioning 3.65 (-2.18 to 9.49) 0.22 1.17 (-4.63 to 6.98) 0.69 
 Bodily pain 4.82 (0.23 to 9.41) 0.040* 4.82 (0.23 to 9.41) 0.040* 
 Emotional well-being -0.32 (-3.68 to 
3.05) 
0.85 -0.63 (-4.03 to 
2.76) 
0.72 
 Energy/fatigue 3.38 (-0.07 to 6.84) 0.055 1.88 (-1.46 to 5.22) 0.27 
 General health 0.86 (-3.02 to 4.74) 0.67 0.47 (-3.53 to 4.47) 0.82 
Anxiety symptoms 
(HADS-A) 
0.08 (-0.58 to 0.73) 0.82 0.42 (-0.22 to 1.06) 0.20 
Depressive symptoms 
(HADS-D) 
-0.20 (-0.86 to 
0.45) 
0.54 -0.16 (0.89 to 0.56) 0.66 
Abbreviations: 95%CI: 95% Confidence Interval; HADS-A: Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D: 
Hospital Anxiety and Depression Scale-Depression subscale; MCS: Mental Component Summary Score; MHNP: mental 
health nurse practitioner; PCS: Physical Component Summary Score; PHQ-15: Patient Health Questionnaire 15-item 
somatic symptom severity scale 
a adjusted for (if necessary): gender, age, level of education, duration of symptoms, somatic symptom severity (PHQ-15), 
anxiety symptoms (HADS-A), depressive symptoms (HADS-D), number of comorbid physical diseases, time interval baseline 
– 2-months follow-up, time interval baseline – 4-months follow-up 





-0.87 (-1.82 to 
0.09) 
0.074 -0.54 (-1.45 to 
0.38) 
0.25 
